Description
ndications |
Listed in Dosage. | ||||||||||||||||||
Dosage |
Adult : PO Constipation 5-10 mg at night. Max: 20 mg. Bowel evacuation 10-20 mg the night before procedure, then 10 mg rectally the next morning. Rectal Constipation As supp/enema: 10 mg in the morning. | ||||||||||||||||||
Dosage Details |
Oral Bowel evacuation Adult: Initially, 10-20 mg the night before the procedure followed by 10 mg rectal supp the next morning. Alternatively, 10 mg on each of the 2 nights before the procedure.
Oral Adult: 5-10 mg at night, up to 20 mg may be given as necessary.
Rectal Adult: As supp or enema: 10 mg in the morning. |
||||||||||||||||||
Administration |
Should be taken on an empty stomach. Do not take w/in 1 hr of antacids, milk or other dairy products. | ||||||||||||||||||
Contraindications |
Acute abdominal conditions (e.g. appendicitis, intestinal inflammatory bowel disease), intestinal obstruction, ileus, severe dehydration, severe abdominal pain associated w/ nausea and vomiting. Presence of anal fissures or ulcerative colitis w/ mucosal damage (rectal). | ||||||||||||||||||
Special Precautions |
Childn. Pregnancy and lactation. | ||||||||||||||||||
Adverse Drug Reactions |
Abdominal discomfort (e.g. colic, cramps), diarrhoea, electrolyte disturbance, nausea, vertigo, vomiting, haematochezia; irritation and proctitis (rectal). Rarely, hypersensitivity reactions (e.g. angioedema, anaphylactoid reactions). | ||||||||||||||||||
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
||||||||||||||||||
Patient Counselling |
This drug may cause dizziness and/or syncope due to vasovagal response (e.g. abdominal spasm), if affected, do not drive or operate machinery. | ||||||||||||||||||
Overdosage |
Symptoms: Diarrhoea, abdominal cramps and excessive loss of water and electrolytes. Management: Induce vomiting or perform gastric lavage. Fluid replacement and electrolyte correction may be required. | ||||||||||||||||||
Drug Interactions |
Risk of dyspepsia and gastric irritation w/ antacids. Increased risk of electrolyte imbalance w/ diuretics or adreno-corticosteroids. | ||||||||||||||||||
Food Interaction |
Increased risk of dyspepsia and gastric irritation w/ milk products. | ||||||||||||||||||
Mechanism of Action |
Description: Bisacodyl stimulates peristalsis by directly irritating the smooth muscle of the large intestine. It alters water and electrolyte secretion, producing net interstitial fluid accumulation and laxation. Onset: 6-12 hr (oral); 15-60 min (supp); 5-20 min(enema). Pharmacokinetics: Absorption: Minimal absorption from the GI tract. Distribution: Volume of distribution: 289 L. Metabolism: Converted to bis(p-hydroxyphenyl)pyridyl-2-methane by intestinal or bacterial enzymes. Excretion: Mainly via faeces; urine (as glucuronide). |
||||||||||||||||||
Storage |
Store below 30°C. | ||||||||||||||||||
MIMS Class |
Laxatives, Purgatives | ||||||||||||||||||
ATC Classification |
A06AB02 – bisacodyl ; Belongs to the class of contact laxatives. | ||||||||||||||||||
